C9ORF72 Mice Point to Gain of Toxic Function in ALS, FTD Does C9ORF72 Repeat RNA Promote Protein Phase Transitions? RNA Regulator Locked Out of Nucleus by C9ORF72 Repeats Listen Up, Gene Silencing Strikes a Chord at RNA Meeting Stressed Out: RNA-binding P
Gantenerumab, Aducanumab: Bobbing Up and Down While Navigating Currents of Trial Design Outcomes, Outcomes: Cognition is Crux of New Alzheimer’s Trials Truly New to Déjà Vu: Investigational Therapy News at CTAD Truly New to Déjà Vu: For Five Hopefuls, Lig
Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting Help for Speech, Swallowing, and Salivation Problems in ALS Does Free Radical Scavenger Edaravone Slow ALS? SOD1, Tau Swept Up in Prion-like Biology at ALS Meeting At the International Sy
Dementia with Lewy Bodies: Is the Research Ready For Clinical Trials Through the Heart? Cardiology Tracer to Nail DLB Diagnosis Dementia with Lewy Bodies: Sharper Image for a Formerly Blurry Disease Brain Imaging: What Does it See in DLB? Lewy Pathology i
Tau Takes Center Stage at 10th Human Amyloid Imaging Conference Tau Tracers Track First Emergence of Tangles in Familial Alzheimer’s Shaky Specificity of Tau PET Ligands Stokes Debate at HAI At HAI, Researchers Explore Diagnostic Potential of a Tau Tracer
Souvenaid Trial Missed Primary, Partially Met Secondary Endpoints New Tack on Aβ Oligomer Role in Disease and Treatment The 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy was held March 9 to 12 in Athens, Greece. Research
AD-Related Dementias Summit 2016: Progress, Aims, Dollars At 2016 Summit, Field Tackles AD-Related Dementias One By One Did you know the U.S. National Alzheimer’s Project Act covers Lewy body, frontotemporal, vascular, and mixed dementias, as well? It doe
Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together? WANTED: Biomarkers for Drug Trials in Frontotemporal Dementia Regulators Tell Frontotemporal Dementia Community: We Play on Your Team Earlier this month in Washington, D.C., 95 scien
Aβ Oligomers Purified from Human Brain Microbial Hypotheses Intrigue at Zilkha Alzheimer’s Meeting What’s Up With the Vasculature in Dementia? At the third annual Zilkha Symposium, held April 15, 2016, in Los Angeles, scientists from the United States and
Keystone Meeting on Microglia/Neurodegeneration: Here’s the Buzz Induced Microglia Make Debut at Keystone Symposium The THIK and Thin of Microglial Surveillance When a Microglia Is No Longer a Microglia Unbiased Screen Fingers TREM2 Ligands That Promote A
In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period. Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials Access: How to Bring People in ‘From the
Frontotemporal Dementia: The Hard Work of Pushing Toward Trials First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running Fluid NfL Shines, Tau PET Dims, in the Hunt for FTD Biomarkers Tests of Social Cognition Hold Potential as FTD Out
At 2nd Kloster Seeon Meeting, Renewed Optimism for Targeting BACE1 What Exactly Does BACE Do in Adults? BACE Inhibition and the Synapse—Insights from Seeon Does BACE Drive Neurites into Dystrophy, Shorting Circuits? Will Next-Gen BACE Inhibitors Dodge Sid
Astrocytes and Exosomes Implicated in Protein Propagation Knock-In Alzheimer’s Mice Catch on More Broadly in the Field Next-Generation Mouse Models: Tau Knock-ins and Human Chimeras Inflammation Helps Microglia Clear Amyloid from AD Brains Exosomes and An
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD Tau PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages Em